CSL to buy Talecris Biotherapeutics for $3.1 billion

HONG KONG (MarketWatch) -- Australia's CSL Ltd., the world's second-largest-plasma products maker, agreed Wednesday to buy Talecris Biotherapeutics Holdings Corp. for $3.1 billion, in a bid to bolster its scale and geographic reach in the $15... 4 months ago